Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL328277 | 0.93 | CNR2 (0.43) | CNR2CNR1GRM5HPGDLMNA | |
| SCHEMBL10126552 | 0.91 | IRAK4 (0.42) | CNR2CNR1GRM5KDM4EALDH1A1 | |
| SCHEMBL10126505 | 0.91 | PTK6 (0.45) | CNR2CNR1GRM5HPGDPTK6 | |
| SCHEMBL17340276 | 0.90 | CNR2 (0.39) | CNR2CNR1GRM5KDM4EALDH1A1 | |
| SCHEMBL16305321 | 0.87 | HPGD (0.50) | CNR2CNR1GRM5KDM4EALDH1A1 | |
| SCHEMBL10156673 | 0.87 | PTK6 (0.39) | CNR2CNR1GRM5NPSR1SMN1; SMN2 | |
| SCHEMBL10127101 | 0.84 | CAMK1D (0.47) | CNR2CNR1 | |
| SCHEMBL10126449 | 0.83 | HPGD (0.42) | CNR2GRM5HPGDBTKMAPT | |
| SCHEMBL10156670 | 0.82 | PPARG (0.41) | ALDH1A1SMN1; SMN2BTKSCN9AMAPT | |
| SCHEMBL10126557 | 0.82 | EPHX2 (0.44) | CNR2CNR1SMN1; SMN2BTKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | CNR2 1453/4885CNR1 1904/4885GRM5 1237/4885 |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | CNR2 1453/4885CNR1 1904/4885GRM5 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.